Biotech IV Monitor

XENE — Xenon Pharmaceuticals Inc.

$6.3B market cap · 7 upcoming readouts tracked

Clinical trial readout dates for Xenon Pharmaceuticals Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is January 2027.

Next readoutJanuary 2027in ~2 months
Upcoming readouts77 Phase 3
Market cap$6.3B
Cash & investments$1.15B~10 quarters at last loss rate
Recent 8-K filings1latest 2026-11-09

Upcoming readouts

Phase 3 Azetukalner
Major Depressive Disorder · NCT06922110
January 2027
Ongoing
Phase 3 XEN1101
Primary Generalized Tonic-Clonic Seizures · NCT05667142
April 2027
Recruiting
Phase 3 Azetukalner
Major Depressive Disorder · NCT07076407
May 2027
Ongoing
Phase 3 XEN1101
Focal Onset Seizures · NCT05716100
January 2028
Recruiting
Phase 3 Azetukalner
Bipolar Disorder; Bipolar Depression · NCT07172516
June 2028
Ongoing
Phase 3 Azetukalner
Bipolar Depression; Bipolar I Disorder · NCT07217860
June 2029
Ongoing
Phase 3 XEN1101
Focal Epilepsy; Tonic-Clonic Seizures · NCT05718817
April 2033
Enrolling

Cash position

Xenon Pharmaceuticals Inc. reported $1.15B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-09). Its net loss for that quarter was $110M; at that rate the cash would last about 10 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Reg FD Disclosure — often a data announcement2026-11-09

Companies working on similar indications

Discussion

No messages yet. If you follow XENE, you can start the conversation.
Track XENE in real time
See live implied volatility for XENE and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on XENE
Contact — questions or corrections about XENE: dukeupt@gmail.com